Trials / Completed
CompletedNCT00482703
A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
A Randomized, Multicenter, Open-label Phase II Study of Dasatinib (BMS-354825) Administered Orally at a Dose of 50mg Twice Daily or 100mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Imatinib
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The objective is to evaluate the cytogenetic response to Dasatinib (BMS-354825) administered for 24 weeks in subjects with Imatinib resistant or intolerant chronic phase chronic myeloid leukemia (CML) once daily (QD) or twice daily. (BID)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dasatinib | tablets, Oral, 100 mg, once daily |
| DRUG | dasatinib | tablets, Oral, 50 mg, twice daily |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2009-05-01
- Completion
- 2009-05-01
- First posted
- 2007-06-05
- Last updated
- 2010-12-17
- Results posted
- 2010-11-30
Locations
9 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00482703. Inclusion in this directory is not an endorsement.